Brosius Mark

SVP Mark Brosius sold 3,658 ISRG shares across 3 days (Mar 3-5) for $1,815,061.50; holdings fell 55.7%

Mark Brosius, SVP & Chief Manufacturing and Supply Chain, executed 3 separate sales totaling 3,658 shares for $1,815,061.50 over three consecutive trading days (March 3–5, 2026) at prices ranging from $488.10 to $498.68, reducing his holdings by 55.7% from 6,564 to 2,906 shares. The blended average sale price of $496.19 sits very close to the current price of $496.70, indicating no material divergence between execution and present valuation. Across his same-ticker history at ISRG, prior sells have not demonstrated well-timed exits—0 of 3 measurable 90-day outcomes show a decline following the sale, suggesting the stock has tended to rise after his prior dispositions at this company. Without a disclosed schedule or plan FLAG, the multi-day spacing and volume of this sale warrant scrutiny against seasonal liquidity or equity-plan vesting, though no such context is provided in the filing.

SVP Mark Brosius sold 4,964 shares of ISRG for $2.7M, reducing holdings by 91.8% to 443 shares

Mark Brosius, SVP & Chief Manufacturing and Supply Chain Officer, executed two separate sales totaling 4,964 shares for $2,717,619.36 between 2025-12-12 and 2025-12-15, leaving him with only 443 shares post-transaction versus 5,407 shares held previously. The blended average sale price of $547.47 sits near the current price of $559.52, though below the 52-week high of $610.45. Notably, his prior four sales at ISRG (all in October 2024) showed positive 90-day returns averaging approximately +16.8%, indicating the stock rose after those earlier divestments; his cross-ticker track record shows a 0.00% well-timed rate across 5 prior sells, meaning none preceded meaningful declines. This substantial reduction in his ISRG holdings—from 91.8% of his prior position—occurs while the company posts strong fundamentals (P/E of 72.20, annual revenue growth of +17.2%, net income of $704.4M in the latest quarter) and represents a material shift in his personal exposure to the company he helps manage manufacturing and supply chain operations.

SVP Brosius sells 2,172 shares of ISRG for $1.1M, reducing holdings by 90.5% from 2.4K shares.

Mark Brosius, SVP & Chief Manufacturing and Supply Chain Officer, executed 4 separate sales totaling 2,172 shares for $1,118,462.96 between October 22–24, 2024, at prices ranging from $510.79 to $515.00. This represents a 90.5% reduction in his holdings, leaving only 229 shares post-transaction. The near-complete exit from a meaningful position occurs as ISRG trades near its 52-week high ($521.15), with the blended average sale price of $514.95 capturing near-peak valuations. Brosius has minimal cross-ticker open-market trading history (1 prior sale), limiting inference from broader pattern analysis. The magnitude and breadth of this reduction—nearly complete liquidation by a senior manufacturing and supply-chain executive—merit investor attention to potential operational context or forward-looking executive sentiment.

Mark Brosius sold 2,115 shares of INTUITIVE SURGICAL (ISGR) at $491.91, reducing holdings by 87.8% to 295 shares.

Mark Brosius executed a substantial sale of 2,115 shares (2.1K shares) at $491.91 on 2024-09-12, reducing his post-transaction holdings to 295 shares from a pre-transaction position of 2,410 shares (2.4K shares). This represents a -87.8% reduction in his direct holdings in INTUITIVE SURGICAL INC (ISGR), a company with strong fundamentals including $2,009,900,000.00 in latest quarterly revenue and net income of $526,900,000.00, coupled with annual revenue growth of +14.5%. The near-complete liquidation of a long position by an insider warrants investor attention, particularly given the company's operational strength and growth trajectory, as it signals a meaningful shift in Brosius's equity stake regardless of broader market context or company performance.